PTGS2 and disease arising from reactivation of latent virus: Our findings also suggest the potential for COX-2 inhibition based therapies in treating angio-proliferative KS lesions as COX-2 silencing, as well as treatment with COX-2 chemical inhibitors, could effectively reduce inflammation, angiogenesis, cell adhesion, cell invasion and cell signaling events during KSHV de novo and latent infection.